Humana Inc. v. Celgene Corp.

Analysis Group supported two of its academic affiliate experts, Dr. Anupam B. Jena and Professor Amitabh Chandra, in developing testimony on behalf of Celgene Corporation in the pharmaceutical company’s successful defense against allegations brought by health insurer Humana, Inc. Humana claimed that Celgene had engaged in improper activities to promote its products, Thalomid and Revlimid, for off-label prescriptions for treatment of cancer and other conditions.

During the five-week jury trial, an Analysis Group team supported Dr. Jena in preparing testimony evaluating off-label claims reimbursed by Humana and assessing causation and damages issues. Analysis Group also supported Professor Chandra in preparing testimony discussing incentives for innovation in the pharmaceutical industry, Celgene’s investment in the development of Thalomid and Revlimid, and the economic value of the two drugs.

The jury found in favor of Celgene on all of the causes of action before it. The Analysis Group team was led by Managing Principals Andree-Anne Fournier and Crystal Pike and Vice President Michaela Johnson.